ArticleBMC neurology2026
Exploring eye movement abnormalities as objective biomarkers for Parkinson's disease utilizing virtual reality-based eye tracking.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOculomotor abnormalities are recognized as potential biomarkers in Parkinson’s disease (PD). However, their broader clinical adoption can be hindered by the accessibility and practicality of assessment tools.
objectiveThis study evaluates a virtual reality (VR)-integrated eye-tracking system for characterizing oculomotor function in PD. We aimed to comprehensively assess oculomotor performance in PD patients compared to healthy controls (HC), investigate its relationship with clinical measures of disease severity, and develop a diagnostic model based on multi-paradigm eye movement parameters to distinguish PD from HC.
methodsEye movements were recorded in 44 PD patients and 34 HC participants during horizontal and vertical saccade, anti-saccade, and smooth pursuit tasks. Parameters were compared between groups and directions. Correlations with duration, disease severity, motor symptoms, medication, and specific eye movement metrics were analyzed. Logistic regression identified key diagnostic predictors, and their performance was evaluated using ROC analysis.
resultsPD patients demonstrated significant oculomotor impairments across multiple tasks, with notably worse performance in the vertical direction compared to the horizontal. Specific parameters, particularly in anti-saccade and smooth pursuit, were significantly correlated with clinical disease severity scores. A diagnostic model combining three key eye movement parameters achieved an AUC of 0.932, showing significantly better discriminatory power than any single parameter alone for distinguishing PD from HC.
conclusionsThis study validates that a multi-parameter oculomotor model can effectively differentiate PD patients from healthy controls. The findings support the value of quantitative eye movement analysis, as a promising auxiliary tool for PD assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.